Progenics Pharmaceuticals (PGNX) 10-K2015 FY Annual report

Filed: 11 Mar 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: AB, Abbreviated, affinity, alleged, alleging, analytical, anatomical, ancillary, ANDA, answered, antiandrogen, antitrust, approach, arrive, artificial, attack, AUC, automated, Aytu, begun, biochemical, Biology, Bioscience, Biovitrum, breakthrough, Bribery, BSI, burden, cabazitaxel, CFO, CI, complement, compression, correctly, create, creating, delisted, Deutschland, device, discovered, distant, efficient, ehf, elevated, Emission, encouraging, evidenced, EXINI, expedited, expressly, Fabbio, family, FCPA, fewer, filgrastim, fluctuation, fluorinated, forecast, formula, futility, genericization, German, Gleason, GmbH, goal, Greece, headquartered, Heidelberg, Hirt, hospice, Iceland, illustrated, indirect, infusion, injunctive, instability, intent, intercompany, investee, jurisdiction, jury, Kabi, Kettering, leader, lesion, lessor, load, located, Lonza, Lund, machine, masking, Merck, methodology, moderate, modified, moiety, monetary, Myelosuppression, Mylan, nearest, noncontrolling, noncurrent, North, Norway, notification, obscured, older, ONALTATM, opposition, outlook, owner, Paragraph, Patrick, pattern, perception, PET, pharmacodynamic, pharmacy, Philidor, physical, physiologic, political, polymer, portal, Positron, precisely, predecessor, predictor, predominant, presence, produce, produced, prompt, provisional, prudent, PTC, publ, purview, PyL, quantification, quantify, quantity, radiographic, radiologic, recreate, recurrent, relocate, remittitur, renew, replicate, reproduce, residual, rest, restitution, Restoration, rolling, routinely, Russia, Rx, safer, saline, sample, scan, scheme, School, scintigraphy, score, serum, Sheldon, showed, showing, Similarly, skeletal, skeleton, slight, slightly, Sloan, Sobi, sophisticated, stable, staffing, stay, stayed, subpopulation, subtype, suit, suitable, Sweden, Swedish, symptomatic, systematic, team, tender, tool, Topography, TOWER, tracer, transient, translated, translation, Translational, treble, truth, UK, unanimously, undergone, unspecified, upheld, uptake, urology, user, UWO, verdict, version, viral, visceral, visibility, visualize, vitro, vivo, voting, wide, WTC, xerostomia

Removed: Adolor, aggregated, angelo, collateralized, decide, diversified, exercisability, founder, Heath, impossible, individual, Israel, joint, jr, loan, lovallo, MedImmune, metabolization, MIP, multicentered, prostectomy, protein, radiotherapy, reclassified, recover, reimbursable, remained, requested, Robert, satisfaction, Science, student, subsidized, summarize, suspended, train, Treasurer

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PGNX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 12.1

Progenics Pharmaceuticals, Inc.

Ratio of (Loss) Earnings to Combined Fixed Charges and Preferred Stock Dividends

(in thousands)

	Years Ended December 31,
	2015			2014		2013			2012			2011
Determination of (loss) earnings:
(Loss) income from operations	$	(39,119	)	$	4,410	$	(42,934	)	$	(35,431	)	$	10,381
Add:
Fixed charges		373			373		710			410			695

(Loss) earnings, as adjusted	$	(38,746	)	$	4,783	$	(42,224	)	$	(35,021	)	$	11,076

Fixed charges:

Estimate of interest within rental expense		373			373		710			410			695

Fixed charges	$	373		$	373	$	710		$	410		$	695

Preferred stock dividends	$	-		$	-	$	-		$	-		$	-

Ratio of (loss) earnings to fixed charges and preferred stock dividends		*			13		*			*			16
Coverage deficiency amount for total fixed charges and preferred stock dividends ⁽¹⁾	$	39,119		$	-	$	42,934		$	35,431		$	-

⁽¹⁾

For the years ended 2012, 2013 and 2015, the Company's coverage ratio is less than one-to-one and it must generate additional earnings of these specified amounts to achieve a coverage ratio of 1:1.